A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: The best case scenario

Journal of Urology

Volumn 156, Issue 2, 1996, Pages 350-354

  Prestigiacomo, Anthony F ^b   Lilja, Hans ^b   Pettersson, Kim ^b   Wolfert, Robert L ^b   Stamey, Thomas A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Prostate specific antigen; Prostatic hypertrophy; Prostatic neoplasms

Indexed keywords

DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; COMPARATIVE STUDY; HUMAN; IMMUNOASSAY; MALE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATECTOMY; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 0030213487     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65847-6     Document Type: Article

References (13)

1. Christensson, A., Laurell, C.-B. and Lilja, H.: Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem., 194: 755, 1990.
2. Lilja, H., Christensson, A., Dahlén, U., Matikainen, M.-T., Nilsson, O., Pettersson, K. and Lövgren, T.: Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin. Chem., 37: 1618, 1991.
3. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
4. Christensson, A., Björk, T., Nilsson, O., Dahlén, U., Matikainen, M.-T., Cockett, A. T. K., Abrahamsson, P.-A. and Lilja, H.: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J. Urol., 150: 100, 1993.
5. Stamey, T. A., Chen, Z. and Prestigiacomo, A.: Serum prostate specific antigen binding α1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J. Urol., 152: 1510, 1994.
6. Mitrunen, K., Pettersson, K., Piironen, T., Björk, T., Lilja, H. and Lövgren, T.: Dual-label one-step immunoassay for simultaneous measurement of free and total PSA concentrations and ratios in serum. Clin. Chem., 41: 1115, 1995.
7. Wang, T. J., Hill, T., Norton, K., Sokoloff, R., Frankenne, F., Rittenhouse, H. G. and Wolfert, R. L.: Specific immunoassay for free PSA and its clinical relevance. J. Urol., part 2, 153: 295A, abstract 267, 1995.
8. Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S. and Schmid, H. P.: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, suppl., 71: 933, 1993.
9. Stamey, T. A., Prestigiacomo, A. F. and Chen, Z.: Standardization of immunoassays for prostate specific antigen. A different view based on experimental observations. Cancer, 74: 1662, 1994.
10. Stamey, T. A.: Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology, 45: 173, 1995.
11. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T. and Southwick, P. C.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol., 151: 1283, 1994.
12. Komatsu, K., Wehner, N., Prestigiacomo, A. F., Chen, Z. and Stamey, T. A.: Variation of serum prostate specific antigen in 814 men from a screening population: intra-individual assay variation is greater than the repeat assay variation. J. Urol., part 2, 151: 401A, abstract 693, 1994.
13. Stamey, T. A., Prestigiacomo, A. and Komatsu, K.: Physiological variation of serum prostate specific antigen (PSA) from a screening population in the range of 4-10 ng./ml. using the Hybritech Tandem-R PSA assay. J. Urol., part 2, 153: 420A, abstract 765, 1995.